CVRx, Inc. (CVRX)
| Market Cap | 37.56M -86.7% |
| Revenue (ttm) | 61.19M +12.0% |
| Net Income | -51.97M |
| EPS | -1.97 |
| Shares Out | 26.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 272,759 |
| Open | 1.410 |
| Previous Close | 1.425 |
| Day's Range | 1.380 - 1.460 |
| 52-Week Range | 1.255 - 11.300 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 4.58 (+224.82%) |
| Earnings Date | Nov 5, 2026 |
About CVRX
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its... [Read more]
Financial Performance
In 2025, CVRx, Inc.'s revenue was $56.65 million, an increase of 10.45% compared to the previous year's $51.29 million. Losses were -$53.31 million, -11.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price target is $4.58, which is an increase of 224.82% from the latest price.
News
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for pa...
CVRx appoints John Landry as CFO
CVRx (CVRX) announced that John Landry has been appointed CFO, succeeding Jared Oasheim, whose resignation was previously announced. Landry will join the company on October 12, and assume the CFO…
CVRx Appoints John Landry as Chief Financial Officer
Landry Brings Two Decades of Medtech and Public Company Finance Experience Landry Brings Two Decades of Medtech and Public Company Finance Experience
CVRx Responds to Letter from Pointillist Family Office
MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx announces Devoted Health Medicare Advantage coverage policy for Barostim
CVRx (CVRX) announced that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17. Devoted Health, a national health insurance company with the eighth l...
Jorey Chernett urges CVRx board to commence formal sales process
Jorey Chernett, Founder of Pointillist Family Office and beneficial owner of more than 5.5% of the outstanding shares of CVRx (CVRX), delivered a letter to the CVRx Board of Directors…
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market Positio...
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx price target lowered to $5 from $13 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on CVRx (CVRX) to $5 from $13 and keeps an Overweight rating on the shares. CVRx’s Q2 results reflect near-term sales execution and…
CVRx, Inc. Transcript: Canaccord Genuity's 46th Annual Growth Conference
A novel heart failure device targets a large, underserved market with strong Medicare coverage and growing clinical evidence. Execution challenges in sales onboarding are being addressed, while payer coverage is expected to improve following Humana's policy. Leadership remains confident in the strategy and market potential.
CVRx chief revenue officer Robert John to depart
CVRx (CVRX) announced that Robert John, chief revenue officer, will depart the company, and that Paul Verrastro will assume the role of interim head of sales, effective immediately. In his…
CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution Disclosures
SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether CVRx, Inc. (NASDAQ: CVRX) or certain of its executive officers violated state or federal securities laws. The...
CVRx downgraded to Hold from Buy at Lake Street
Lake Street analyst Frank Takkinen downgraded CVRx (CVRX) to Hold from Buy with a price target of $3.50, down from $14. The firm says its downgrade does not reflect any…
CVRx downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded CVRx (CVRX) to Hold from Buy with a price target of $4, down from $12. the company materially lowered its guidance due to a slower territory manager productivity…
CVRx price target lowered to $5 from $10 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on CVRx (CVRX) to $5 from $10 and keeps a Buy rating on the shares. The firm said they reported a…
CVRx downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Matt O’Brien downgraded CVRx (CVRX) to Neutral from Overweight with a price target of $4, down from $12, following the Q2 report. The company lowered its full…
CVRx, Inc. Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 16% year-over-year to $15.7M with an 87% gross margin, but sales force turnover and payer headwinds led to lowered full-year guidance. U.S. growth remains strong in stable regions, while investments in training and field support aim to address execution gaps.
CVRx, Inc. Earnings release: Q2 2026
CVRx, Inc. released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
CVRx, Inc. Quarterly report: Q2 2026
CVRx, Inc. has published its Q2 2026 quarterly earnings report on August 6, 2026.
CVRx Reports Second Quarter 2026 Financial and Operating Results
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx, Inc. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Leadership transition is underway with a structured CFO succession plan. Barostim therapy targets a $10B+ U.S. market, supported by strong clinical and real-world evidence. Improved reimbursement, a revamped sales force, and rising center productivity are driving 2024 growth, with a robust financial position and focus on U.S. expansion.
CVRx CFO Jared Oasheim to step down
CVRx (CVRX) announced that Jared Oasheim, the company’s CFO, will be stepping down from his role to pursue other professional opportunities. To support a transition, Oasheim will remain with the…